ClinicalTrials.gg
Active, not recruitingNCT04619004Updated Nov 2, 2026Results posted

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

A Phase 2 interventional study of Patritumab Deruxtecan (Fixed dose) and Patritumab Deruxtecan (Up-Titration) in Non-Small Cell Lung Cancer Metastatic and Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor, sponsored by Daiichi Sankyo. Active, not recruiting at 123 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Daiichi Sankyo · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
277
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 41 studies in Carcinoma, Non-Small-Cell Lung by Daiichi Sankyo — 5 open to participants now, 16 under way, 5 of them phase 3. Carcinoma, Non-Small-Cell Lung · Daiichi Sankyo.

Enrollment
12th of 31
277 · median 181
Started
2021
with 3 others
Phase 2
10 of 41
1 open now
Primary completion
2022-11
later than 0 of 15 live
Registered
23rd of 41
by date

Among the 41 studies in Carcinoma, Non-Small-Cell Lung by Daiichi Sankyo, this one is the 12th largest by enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2021, is one of 10 in phase 2, reaches primary completion later than 0 of the 15 other live ones, and was the 23rd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

5 of the 41 studies in Carcinoma, Non-Small-Cell Lung by Daiichi Sankyo are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Carcinoma, Non-Small-Cell Lung by Daiichi Sankyo, or all of them as a file.
02

Study summary

This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an activating EGFR mutation (exon 19 deletion or L858R) who have received and progressed on or after at least 1 EGFR TKI and 1 platinum-based chemotherapy-containing regimen.

Read the detailed description

This study will initially randomize participants to one of 2 arms in a 1:1 ratio to receive either a 5.6 mg/kg fixed dose regimen or an up-titration dose regimen of patritumab deruxtecan (HER3-DXd, U3-1402).

03

Conditions studied

  • Non-Small Cell Lung Cancer Metastatic
  • Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

Keywords

  • Non-Small Cell Lung Cancer Metastatic
  • Non-Small Cell Lung Cancer with Mutation in Epidermal Growth Factor Receptor
  • Epidermal growth factor receptor
  • HER3-DXd
  • Patritumab Deruxtecan
  • U3-1402
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must meet all of the following criteria to be eligible for inclusion in this study.

  • Sign and date the tissue form (ICF) and the main ICF, prior to the start of any study-specific qualification procedures.
  • Male or female participants aged ≥18 years (follow local regulatory requirements if the legal age of consent for study participation is >18 years old).
  • or cytologically documented locally advanced or NSCLC not amenable to curative surgery or radiation.
  • Documentation of radiological disease progression while on/after receiving most recent treatment regimen for locally advanced or metastatic disease. Participants must have received both of the following:

    • Prior treatment with osimertinib. Participants receiving an EGFR TKI at the time of signing informed consent should continue to take the EGFR TKI until 5 days prior to Cycle 1 Day 1. Participants in South Korea known to harbor a clinically actionable genomic alteration in addition to EGFR mutation (e.g., anaplastic lymphoma kinase [ALK] or ROS1 protocol oncogene 1 [ROS1] fusion) for which treatment is available must have also received prior treatment with at least 1 approved genotype-directed therapy, unless unable (i.e., if ). No new testing for these genomic alterations (e.g., ALK or ROS1 fusion) is required for Screening.
    • Systemic therapy with at least 1 platinum-based chemotherapy regimen.
  • Documentation of an EGFR-activating mutation detected from tumor tissue or blood sample: exon 19 deletion or L858R.
  • At least 1 confirmed by BICR as per v1.1
  • Consented and willing to provide required tumor tissue of sufficient quantity and of adequate tumor tissue content. Required tumor tissue can be provided as either:

    • Pretreatment tumor from at least 1 lesion not previously irradiated and amenable to core biopsy OR
    • Archival tumor tissue collected from a biopsy performed within 3 months prior to signing of the tissue consent and since progression while on or after treatment with the most recent cancer therapy regimen.
  • Performance Standard of 0 or 1 at Screening.
  • Has adequate bone marrow reserve and organ function based on local laboratory data within 14 days prior to Cycle 1 Day 1:

    • count : ≥100,000/mm\^3 or ≥100 × 10\^9/L (platelet transfusions are not allowed up to 14 days prior to Cycle 1 Day 1 to meet eligibility)
    • : ≥9.0 g/dL (transfusion and/or growth factor support is allowed)
    • : ≥1500/mm\^3 or ≥1.5 × 10\^9/L
    • Serum creatinine (SCr) or (CrCl): SCr ≤1.5 × (ULN), OR CrCl ≥30 mL/min as calculated using the Cockcroft-Gault equation or measured CrCl
    • /alanine aminotransferase: ≤3 × ULN (if liver metastases are present, ≤5 × ULN)
    • Total : ≤1.5 × ULN if no liver metastases (\<3 × ULN in the presence of documented Gilbert's syndrome [unconjugated hyperbilirubinemia] or liver metastases)
    • Serum albumin: ≥2.5 g/dL
    • (PT) or PT-International normalized ratio (INR) and activated partial thromboplastin time (aPTT)/PTT: ≤1.5 × ULN, except for subjects on coumarin-derivative anticoagulants or other similar anticoagulant therapy, who must have PT-INR within therapeutic range as deemed appropriate by the Investigator

Exclusion criteria

Exclusion Criteria:

Participants meeting any exclusion criteria for this study will be excluded from this study.

  • Any previous histologic or cytologic evidence of small cell OR combined small cell/non-small cell disease in the or pretreatment tumor biopsy.
  • Any history of interstitial lung disease (including pulmonary fibrosis or radiation pneumonitis), has current interstitial lung disease (ILD), or is suspected to have such disease by imaging during screening.
  • Clinically severe respiratory compromise (based on Investigator's assessment) resulting from intercurrent pulmonary illnesses including, but not limited to:

    • Any underlying pulmonary disorder (eg, pulmonary emboli within 3 months prior to the study enrollment, severe asthma, severe [COPD]), restrictive lung disease, pleural effusion);
    • Any , connective tissue or inflammatory disorders with pulmonary involvement (eg, rheumatoid arthritis, Sjogren's syndrome, sarcoidosis); OR prior complete pneumonectomy.
  • Is receiving chronic systemic dosed at >10 mg prednisone or equivalent anti-inflammatory or any form of therapy prior to enrollment. Participants who require use of bronchodilators, inhaled or topical steroids, or local steroid injections may be included in the study.
  • Evidence of any .
  • Evidence of clinically active spinal cord compression or .
  • Inadequate prior to Cycle 1 Day 1, defined as:

    • Whole brain radiation therapy \<14 days or stereotactic brain radiation therapy \<7 days;
    • Any cytotoxic chemotherapy, agent or other anticancer drug(s) from a previous cancer treatment regimen or clinical study (other than EGFR TKI), \<14 days or 5 half-lives, whichever is longer;
    • Monoclonal antibodies, other than , such as bevacizumab (anti-VEGF) and cetuximab (anti-EGFR) \<28 days;
    • Immune checkpoint inhibitor therapy \<21 days;
    • Major surgery (excluding placement of vascular access) \<28 days;
    • Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation \<28 days or palliative radiation therapy \<14 days; or
    • Chloroquine or hydroxychloroquine \<14 days.
  • Prior treatment with an anti-human epidermal growth factor receptor 3 (HER3) antibody or single-agent topoisomerase I inhibitor.
  • Prior treatment with an antibody drug conjugate (ADC) that consists of any topoisomerase I inhibitor
  • Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to National Cancer Institute (NCI-CTCAE) v5.0, Grade ≤1 or baseline. Participants with chronic Grade 2 toxicities may be eligible at the discretion of the Investigator after consultation with the Sponsor Medical Monitor or designee.
  • Has history of other active within 3 years prior to enrollment, except:

    • Adequately treated non-melanoma skin cancer;
    • Superficial bladder tumors (Ta, Tis, T1);
    • Adequately treated intraepithelial carcinoma of the cervix uteri;
    • Low risk non- prostate cancer (with Gleason score \<7, and following local treatment or ongoing active surveillance);
    • Any other curatively treated in situ disease.
  • Uncontrolled or significant cardiovascular disease prior to Cycle 1 Day 1
  • Active and/or infection, such as those with serologic evidence of viral infection within 28 days of Cycle 1 Day 1.
  • Participant with any (HIV) infection.
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
277 participants (actual)

Study arms

  • Experimental
    Study Group 1: Patritumab deruxtecan 5.6 mg/kg

    Study Group 1 will be participants with metastatic or locally advanced NSCLC with an EGFR-activating mutation randomized to receive patritumab deruxtecan 5.6 mg/kg IV every 3 weeks (Q3W)

    Drug: Patritumab Deruxtecan (Fixed dose)

  • Experimental
    Study Group 2: Patritumab deruxtecan Up-Titration

    Study Group 2 will be participants with metastatic or locally advanced NSCLC with an EGFR-activating mutation randomized to receive patritumab deruxtecan up-titration IV every 3 weeks (Q3W)

    Drug: Patritumab Deruxtecan (Up-Titration)

Interventions

  • Patritumab deruxtecan will be dosed at 5.6 mg/kg as an intravenous (IV) infusion administered on Day 1 of each 21-day cycle.

    Also known as: U3-1402, HER3-DXd

  • Patritumab deruxtecan will be dosed as an intravenous (IV) infusion administered at Cycle 1, 3.2 mg/kg; Cycle 2, 4.8 mg/kg; Cycle 3 and subsequent cycles, 6.4 mg/kg administered on Day 1 of each 21-day cycle.

    Also known as: U3-1402, HER3-DXd

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR)

    ORR is defined as the proportion of participants with a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) as assessed by BICR per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions based on RECIST v1.1.

    Time frame: Data collected from screening until time of disease progression by BICR, death, lost to follow up, study discontinuation, whichever occurs first, assessed up to approximately 21 months

Secondary outcomes

  1. Duration of Response (DoR)

    DoR is defined as the time from the first documented confirmed response (CR or PR) to the date of progression or death due to any cause as assessed by BICR and Investigator per RECIST v1.1, respectively. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions.

    Time frame: Data collected from screening until time of disease progression by BICR, death, lost to follow up, study discontinuation, whichever occurs first, assessed up to approximately 21 months

  2. Progression-free Survival (PFS)

    PFS is defined as the time from the start of study treatment to the first documentation of objective progressive disease (PD) per RECIST v1.1 or death due to any cause. PFS will be determined by BICR and by Investigator, respectively.

    Time frame: Data collected from screening until time of disease progression by BICR, death, lost to follow up, study discontinuation, whichever occurs first, assessed up to approximately 21 months

  3. Objective Response Rate (ORR) as Assessed by the Investigator

    ORR is defined as the proportion of participants with a BOR of confirmed CR or confirmed PR as assessed by the Investigator per RECIST v1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions.

    Time frame: Data collected from screening until time of disease progression, death, lost to follow up, study discontinuation, whichever occurs first, assessed up to approximately 21 months

  4. Disease Control Rate (DCR)

    DCR is defined as the proportion of participants who achieved a BOR of confirmed CR, confirmed PR, or stable disease (SD) as assessed by BICR and by the Investigator per RECIST v1.1, respectively. CR was defined as a disappearance of all target lesions, PR was defined as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions.

    Time frame: Data collected from screening until time of disease progression by BICR, death, lost to follow up, study discontinuation, whichever occurs first, assessed up to approximately 21 months

  5. Time to Tumor Response (TTR)

    TTR is defined as the time from the start of study treatment to the date of the first documentation of confirmed response (CR or PR) as assessed by BICR and Investigator per RECIST v1.1, respectively. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions.

    Time frame: Data collected from screening until time of disease progression by BICR, death, lost to follow up, study discontinuation, whichever occurs first, assessed up to approximately 21 months

  6. Best Percentage Change in the Sum of Diameters (SoD) of Measurable Tumors

    The best percentage change in the SoD of measurable tumors is defined as the percentage change in the smallest SoD from all post-baseline tumor assessments, taking as reference the baseline SoD.

    Time frame: Data collected from screening until time of disease progression by BICR, death, lost to follow up, study discontinuation, whichever occurs first, assessed up to approximately 21 months

  7. Overall Survival (OS)

    OS defined as the time from the start of study treatment to the date of death due to any cause.

    Time frame: Death date is collected until the participant discontinues the study or up to approximately 45 months

  8. Incidence of Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESIs)

    A TEAE is defined as an adverse event (AE) with a start or worsening date during the on-treatment period. A serious AE is defined as any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is an important medical event, or may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes noted. AESIs will also be assessed. Adverse events will be coded using MedDRA and will be graded using NCI-CTCAE v5.0.

    Time frame: From baseline up to Day 47 post last dose

07

Results

Posted Apr 2, 2024

Participant flow

A total of 277 participants were enrolled and randomized to treatment at clinical sites in the United States, Japan, Republic of Korea, Singapore, Taiwan, Austria, Belgium, Bulgaria, France, Germany, Italy, Netherlands, Spain, United Kingdom, and Australia. Two participants did not receive any treatment. (1 person in each treatment arm).

Participant flow — Overall Study
MilestonePatritumab Deruxtecan 5.6 mg/kgPatritumab Deruxtecan Up-Titration
Started22651
Completed8714
Not completed13937
Withdrew: Death11428
Withdrew: Lost to follow-up11
Withdrew: Withdrawal by subject247
Withdrew: Other - not specified01

Outcome measures

PrimaryObjective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR)

ORR is defined as the proportion of participants with a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) as assessed by BICR per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions based on RECIST v1.1.

Time frame:
Data collected from screening until time of disease progression by BICR, death, lost to follow up, study discontinuation, whichever occurs first, assessed up to approximately 21 months
Reported as:
Count of participants · Participants
Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR)
ParticipantsPatritumab Deruxtecan 5.6 mg/kgPatritumab Deruxtecan Up-Titration
Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR)648
SecondaryDuration of Response (DoR)

DoR is defined as the time from the first documented confirmed response (CR or PR) to the date of progression or death due to any cause as assessed by BICR and Investigator per RECIST v1.1, respectively. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions.

Time frame:
Data collected from screening until time of disease progression by BICR, death, lost to follow up, study discontinuation, whichever occurs first, assessed up to approximately 21 months
Reported as:
Median · months
Duration of Response (DoR)
monthsPatritumab Deruxtecan 5.6 mg/kgPatritumab Deruxtecan Up-Titration
Duration of response (BICR)6.0 (4.4 to 7.2)7.1 (2.8 to 15.2)
Duration of response (Investigator)6.9 (5.6 to 7.2)5.1 (2.6 to 9.5)
SecondaryProgression-free Survival (PFS)

PFS is defined as the time from the start of study treatment to the first documentation of objective progressive disease (PD) per RECIST v1.1 or death due to any cause. PFS will be determined by BICR and by Investigator, respectively.

Time frame:
Data collected from screening until time of disease progression by BICR, death, lost to follow up, study discontinuation, whichever occurs first, assessed up to approximately 21 months
Reported as:
Median · months
Progression-free Survival (PFS)
monthsPatritumab Deruxtecan 5.6 mg/kgPatritumab Deruxtecan Up-Titration
Progression-free survival (BICR)5.5 (5.1 to 5.9)6.7 (4.2 to 8.8)
Progression-free survival (Investigator)5.5 (4.2 to 5.7)5.3 (4.0 to 8.2)
SecondaryObjective Response Rate (ORR) as Assessed by the Investigator

ORR is defined as the proportion of participants with a BOR of confirmed CR or confirmed PR as assessed by the Investigator per RECIST v1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions.

Time frame:
Data collected from screening until time of disease progression, death, lost to follow up, study discontinuation, whichever occurs first, assessed up to approximately 21 months
Reported as:
Count of participants · Participants
Objective Response Rate (ORR) as Assessed by the Investigator
ParticipantsPatritumab Deruxtecan 5.6 mg/kgPatritumab Deruxtecan Up-Titration
Objective Response Rate (ORR) as Assessed by the Investigator568
SecondaryDisease Control Rate (DCR)

DCR is defined as the proportion of participants who achieved a BOR of confirmed CR, confirmed PR, or stable disease (SD) as assessed by BICR and by the Investigator per RECIST v1.1, respectively. CR was defined as a disappearance of all target lesions, PR was defined as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions.

Time frame:
Data collected from screening until time of disease progression by BICR, death, lost to follow up, study discontinuation, whichever occurs first, assessed up to approximately 21 months
Reported as:
Count of participants · Participants
Disease Control Rate (DCR)
ParticipantsPatritumab Deruxtecan 5.6 mg/kgPatritumab Deruxtecan Up-Titration
Disease control rate (BICR)16638
Disease control rate (Investigator)16937
SecondaryTime to Tumor Response (TTR)

TTR is defined as the time from the start of study treatment to the date of the first documentation of confirmed response (CR or PR) as assessed by BICR and Investigator per RECIST v1.1, respectively. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions.

Time frame:
Data collected from screening until time of disease progression by BICR, death, lost to follow up, study discontinuation, whichever occurs first, assessed up to approximately 21 months
Reported as:
Mean · months
Time to Tumor Response (TTR)
monthsPatritumab Deruxtecan 5.6 mg/kgPatritumab Deruxtecan Up-Titration
Time to response (BICR)2.2 ± 1.311.7 ± 0.61
Time to response (Investigator)2.5 ± 1.782.1 ± 1.09
SecondaryBest Percentage Change in the Sum of Diameters (SoD) of Measurable Tumors

The best percentage change in the SoD of measurable tumors is defined as the percentage change in the smallest SoD from all post-baseline tumor assessments, taking as reference the baseline SoD.

Time frame:
Data collected from screening until time of disease progression by BICR, death, lost to follow up, study discontinuation, whichever occurs first, assessed up to approximately 21 months
Reported as:
Mean · percentage change from baseline
Best Percentage Change in the Sum of Diameters (SoD) of Measurable Tumors
percentage change from baselinePatritumab Deruxtecan 5.6 mg/kgPatritumab Deruxtecan Up-Titration
Sum of diameters (BICR)-25.66 ± 30.39-17.48 ± 29.54
Sum of diameters (Investigator)-20.84 ± 27.01-11.46 ± 29.25
SecondaryOverall Survival (OS)

OS defined as the time from the start of study treatment to the date of death due to any cause.

Time frame:
Death date is collected until the participant discontinues the study or up to approximately 45 months

Results for this outcome have not been posted.

SecondaryIncidence of Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESIs)

A TEAE is defined as an adverse event (AE) with a start or worsening date during the on-treatment period. A serious AE is defined as any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is an important medical event, or may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes noted. AESIs will also be assessed. Adverse events will be coded using MedDRA and will be graded using NCI-CTCAE v5.0.

Time frame:
From baseline up to Day 47 post last dose

Results for this outcome have not been posted.

Adverse events

Collected over Adverse events were collected from after first dose up to 47 days post last dose, up to approximately 21 months (primary outcome data cutoff date).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Patritumab Deruxtecan 5.6 mg/kg114/225 (50.7%)90/225 (40%)223/225 (99.1%)
Patritumab Deruxtecan Up-Titration28/50 (56%)16/50 (32%)49/50 (98%)
Most frequent serious events
Showing 10 of 86
Most frequent serious events
EventPatritumab Deruxtecan 5.6 mg/kgPatritumab Deruxtecan Up-Titration
Disease progressionGeneral disorders11/2254/50
PneumonitisRespiratory, thoracic and mediastinal disorders9/2251/50
Pleural effusionRespiratory, thoracic and mediastinal disorders4/2252/50
AnaemiaBlood and lymphatic system disorders6/2250/50
PneumoniaInfections and infestations5/2250/50
NauseaGastrointestinal disorders5/2251/50
Febrile neutropeniaBlood and lymphatic system disorders5/2250/50
PyrexiaGeneral disorders3/2251/50
Respiratory failureRespiratory, thoracic and mediastinal disorders3/2251/50
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/2251/50
Most frequent other events
Showing 10 of 51
Most frequent other events
EventPatritumab Deruxtecan 5.6 mg/kgPatritumab Deruxtecan Up-Titration
NauseaGastrointestinal disorders147/22532/50
Decreased appetiteMetabolism and nutrition disorders92/22521/50
ConstipationGastrointestinal disorders77/22515/50
AnaemiaBlood and lymphatic system disorders74/22515/50
FatigueGeneral disorders69/22512/50
Neutrophil count decreasedInvestigations61/22515/50
Platelet count decreasedInvestigations65/22513/50
DiarrhoeaGastrointestinal disorders62/22511/50
VomitingGastrointestinal disorders60/22511/50
AlopeciaSkin and subcutaneous tissue disorders57/2250/50

Baseline characteristics

Demographic and baseline characteristics were reported from the Full Analysis Set.

Age, Continuous
Age, Continuous(years)Patritumab Deruxtecan 5.6 mg/kgPatritumab Deruxtecan Up-TitrationTotal
Mean62.7 ± 9.8659.8 ± 10.0762.2 ± 9.95
Age, Customized
Age, Customized(Participants)Patritumab Deruxtecan 5.6 mg/kgPatritumab Deruxtecan Up-TitrationTotal
<65 years12236158
≥65 years10415119
<75 years20149250
≥75 years25227
Sex: Female, Male
Sex: Female, Male(Participants)Patritumab Deruxtecan 5.6 mg/kgPatritumab Deruxtecan Up-TitrationTotal
Female13329162
Male9322115
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Patritumab Deruxtecan 5.6 mg/kgPatritumab Deruxtecan Up-TitrationTotal
Asian10632138
Black or African-American314
Native Hawaiian or Other Pacific Islander101
White9215107
Other24327
08

Study locations

123 sites

Showing the first 100 of 123 sites across 16 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Yu HA, Goto Y, Janne PA. A study to learn how well HER3-DXd (patritumab deruxtecan) works and how safe it is in people with previously treated non-small-cell lung cancer that has a mutation in the EGFR gene: a plain language summary of the HERTHENA-Lung01 study. Future Oncol. 2026 Oct 12:1-16. doi: 10.1080/14796694.2026.2691681. Online ahead of print. PubMed 42860885 ↗
  • Patel J, Meng J, Le H, Tanaka Y, Phani S, Salas M, Wu C, Sternberg D, Esker S, Anderson JP, Crowley A, Zhou SQ, Lieb C, Sun H, Doan QV, Santhanagopal A, Reckamp KL. Real-World Treatment Patterns and Clinical Outcomes Among Patients with Metastatic or Unresectable EGFR-Mutated Non-Small Cell Lung Cancer Previously Treated with Osimertinib and Platinum-Based Chemotherapy. Adv Ther. 2024 Aug;41(8):3299-3315. doi: 10.1007/s12325-024-02936-4. Epub 2024 Jul 3. PubMed 38958845 ↗
  • Yu HA, Goto Y, Hayashi H, Felip E, Chih-Hsin Yang J, Reck M, Yoh K, Lee SH, Paz-Ares L, Besse B, Bironzo P, Kim DW, Johnson ML, Wu YL, John T, Kao S, Kozuki T, Massarelli E, Patel J, Smit E, Reckamp KL, Dong Q, Shrestha P, Fan PD, Patel P, Sporchia A, Sternberg DW, Sellami D, Janne PA. HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy. J Clin Oncol. 2023 Dec 10;41(35):5363-5375. doi: 10.1200/JCO.23.01476. Epub 2023 Sep 10. PubMed 37689979 ↗
  • Yu HA, Yang JC, Hayashi H, Goto Y, Felip E, Reck M, Vigliotti M, Dong Q, Cantero F, Fan PD, Kanai M, Sternberg DW, Janne PA. HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC. Future Oncol. 2023 Jun;19(19):1319-1329. doi: 10.2217/fon-2022-1250. Epub 2023 May 22. PubMed 37212796 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.

Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

Data sharing details ↗ · vivli.org

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Nov 2022, 21 months.

Results were first posted in Apr 2024, 1 year 4 months after primary completion.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 21 months is below that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2020
First posted
Nov 6, 2020
StartActual
Feb 2, 2021
Primary completionActual
Nov 21, 2022
CompletionEst.
Jan 4, 2027
Results first posted
Apr 2, 2024
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42860885 ↗
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42860885 ↗
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04619004
Lead sponsor
Daiichi Sankyo
Responsible party
Sponsor
First posted
Nov 6, 2020
Start date
Feb 2, 2021
Primary completion
Nov 21, 2022
Completion
Jan 4, 2027 (estimated)
Results posted
Apr 2, 2024
Last update
Nov 2, 2026

Study contacts

Medical Director
study director · Daiichi Sankyo

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Patritumab deruxtecan

Start the discussion